On February 23, 2018, in a much-anticipated decision, the PTAB ruled that tribal sovereign immunity could not be used to shield certain Allergan Inc. (“Allergan”) patents from review in a number of IPRs. Allergan had assigned...more
2/28/2018
/ Allergan Inc ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
IP License ,
Native American Issues ,
Patent Invalidity ,
Patent Ownership ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Post-Grant Review ,
Sovereign Immunity ,
Tribal Governments